Journal
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Volume 81, Issue 4, Pages 283-289Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2014.12.009
Keywords
LEADER; Linezolid; Oxazolidinones
Categories
Funding
- Pfizer
- Pfizer via the SENTRY Antimicrobial Surveillance Program platform
- Achaogen
- Actelion
- Affinium
- American Proficiency Institute
- AmpliPhi Bio
- Anacor
- Astellas
- AstraZeneca
- Basilea
- BioVersys
- Cardeas
- Cempra
- Cerexa
- Cubist
- Daiichi
- Dipexium
- Durata
- Fedora
- Forest Research Institute
- Furiex
- Genentech
- GlaxoSmithKline
- Janssen
- Johnson Johnson
- Medpace
- Meiji Seika Kaisha
- Melinta
- Merck
- Methylgene
- Nabriva
- Nanosphere
- Novartis
- Polyphor
- Rempex
- Roche
- Seachaid
- Shionogi
- Synthes
- Medicines Co.
- Theravance
- Thermo Fisher
- Venatorx
- Vertex
- Waterloo
Ask authors/readers for more resources
The 2013 LEADER surveillance program monitored the in vitro activity of linezolid and comparator agents against Gram-positive bacteria at 60 medical centers in the United States. A total of 7183 pathogens were contributed from 6 predetermined pathogen groups. The groups were Staphylococcus aureus, coagulase-negative staphylococci, enterococci, Streptococcus pneumoniae,beta-hemolytic streptococci, and viridans group streptococci. The MIC90 value for each of the 6 pathogen groups was 1 mu g/mL. Susceptibility of all organisms to linezolid was 99.83%. Only 12 isolates (2 S. aureus, 3 Staphylococcus epidermidis, 1 Streptococcus sanguinis, 5 Enterococcus faecium, and 1 Enterococcus faecalis) were nonsusceptible to linezolid (0.17%). Three of these (2 S. aureus and 1 E. faecium) harbored the cfr resistance mechanism. The findings indicate that linezolid activity remains stable, although there are examples of clonal dissemination within several monitored institutions. (C) 2015 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available